Data / Form D filings / CrossBridge Bio, Inc.
CrossBridge Bio, Inc.: Form D filing
CrossBridge Bio, Inc., a biotechnology company in Houston, TX, filed a Form D with the SEC in 2024. The latest, on November 4, 2024, reports $10.8 million sold of a $17 million offering to 23 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2450 HOLCOMBE BLVD, SUITE X, Houston, TX, 77021
- Phone
- (346) 547-5202
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- United States
- Year incorporated
- 2023
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2043521
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 4, 2024 | New notice | $17,019,978 | $10,818,821 | $6,201,157 | 23 | Oct 29, 2024 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| William F. McKeon | Director | |
| Kyoji Tsuchikama | Executive Officer, Director, Promoter | |
| Damir F. Illich | Director | |
| Patrick James Crutcher | Director | |
| Michael Torres | Executive Officer, Director, Promoter | |
| Zhiqiang F. An | Promoter |
Other biotechnology companies in Texas that filed recently
- Nuclein, LLC $15.7 million · Oct 27, 2026
- OncoNano Medicine, Inc. $10.1 million · Oct 8, 2026
- Solaris Endovascular Inc. $5 million · Oct 1, 2026
- Hera Biotech, Inc. $1.7 million · Sep 23, 2026
- Kayak Therapeutics, Inc. $25 million · Aug 21, 2026
- InnovoTEX Inc. $2.7 million · Aug 18, 2026
Every Form D from the week of Nov 4, 2024 · All recent filings in Texas · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what CrossBridge Bio, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.